Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study.

BACKGROUND Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12. METHODS On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and underwent training on proper use. Insertion of the first sensor was performed under staff supervision. Subjects inserted subsequent sensors on their own. After calibration, the device (a 3-day sensor, receiver, and transmitter) provided users with real-time glucose values updated at 5-min intervals, glucose trend graphs, configurable high/low alerts, and a hypoglycemia alarm (<or=55 mg/dL). Study participants were given supplies sufficient for 3 weeks of device use. Follow-up visits were performed at 3-week intervals for resupply and to download CGM data, with a final visit at the end of week 12. RESULTS Overall, a reduction in HbA1c of 0.4 +/- 0.05% (least squares mean +/- SE) was observed, P < 0.0001. Significant HbA1c reductions were observed across subgroups of subjects with both type 1 and 2 diabetes, and those delivering insulin by multiple daily injections and pumps. The largest HbA1c reduction (1.4 +/- 0.4%) was observed in subjects with baseline HbA1c >9.0%. Increased CGM use was associated with greater reductions in HbA1c. CONCLUSIONS This observational study showed that home use of real-time GCM was safe and well tolerated and associated with a clinically and statistically significant reduction in HbA1c. Large-scale randomized, controlled outcome studies of CGM are indicated.

[1]  D. Klonoff.  Continuous glucose monitoring: roadmap for 21st century diabetes therapy. , 2005, Diabetes care.

[2]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[3]  P. Cryer,et al.  Hypoglycemia in diabetes. , 2003, Diabetes care.

[4]  H. Chase,et al.  Use of the GlucoWatch biographer in children with type 1 diabetes. , 2003, Pediatrics.

[5]  Howard Zisser,et al.  Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. , 2006, Diabetes care.

[6]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[7]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, JAMA.

[8]  R. Schiaffini,et al.  The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk , 2002, Diabetes/metabolism research and reviews.

[9]  F. Kaufman,et al.  A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. , 2001, Diabetes care.

[10]  H. Chase,et al.  Continuous subcutaneous glucose monitoring in children with type 1 diabetes. , 2001, Pediatrics.

[11]  R. Gerard.  Continuous glucose monitoring and diabetes health outcomes: a critical appraisal. , 2008 .

[12]  B. Zinman,et al.  Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. , 2001, Diabetes care.

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  I. Hirsch,et al.  Should minimal blood glucose variability become the gold standard of glycemic control? , 2005, Journal of diabetes and its complications.

[15]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[16]  The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial , 1995, Diabetes.

[17]  Claresa Levetan,et al.  Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. , 2004, Mayo Clinic proceedings.

[18]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[19]  Richard M Hoffman,et al.  Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). , 2003, Diabetes care.

[20]  E. Biermann,et al.  How would patients behave if they were continually informed of their blood glucose levels? A simulation study using a "virtual" patient. , 2008, Diabetes technology & therapeutics.

[21]  Hiroyuki Kudo,et al.  Glucose sensor using a phospholipid polymer-based enzyme immobilization method , 2008, Analytical and bioanalytical chemistry.

[22]  Johnny Ludvigsson,et al.  Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. , 2003, Pediatrics.

[23]  Robert Cuddihy,et al.  Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. , 2008, Diabetes technology & therapeutics.

[24]  H Peter Chase,et al.  A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. , 2005, Diabetes care.

[25]  E. Brugués,et al.  Real-time continuous glucose monitoring together with telemedical assistance improves glycemic control and glucose stability in pump-treated patients. , 2008, Diabetes technology & therapeutics.

[26]  A. Novials,et al.  The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. , 2003, Diabetes care.

[27]  L. Jovanovic,et al.  Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values , 2006, Diabetes Care.

[28]  J. Mastrototaro,et al.  Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. , 1999, Diabetes research and clinical practice.

[29]  P. Schaepelynck-Belicar,et al.  Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). , 2003, Diabetes & metabolism.